WINTON GROUP Ltd lifted its stake in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) by 116.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,514 shares of the medical instruments supplier’s stock after buying an additional 12,627 shares during the quarter. WINTON GROUP Ltd owned about 0.12% of LeMaitre Vascular worth $658,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its position in shares of LeMaitre Vascular by 66,640.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 3,337 shares of the medical instruments supplier’s stock worth $103,000 after buying an additional 3,332 shares during the period. Municipal Employees Retirement System of Michigan acquired a new stake in shares of LeMaitre Vascular during the 4th quarter worth approximately $106,000. Metropolitan Life Insurance Co. NY grew its position in shares of LeMaitre Vascular by 373.8% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,629 shares of the medical instruments supplier’s stock worth $133,000 after buying an additional 4,441 shares during the period. BB&T Corp acquired a new stake in shares of LeMaitre Vascular during the 1st quarter worth approximately $203,000. Finally, Globeflex Capital L P grew its position in shares of LeMaitre Vascular by 26.5% during the 1st quarter. Globeflex Capital L P now owns 6,578 shares of the medical instruments supplier’s stock worth $204,000 after buying an additional 1,378 shares during the period. 78.24% of the stock is owned by institutional investors.

NASDAQ LMAT traded down $0.24 during mid-day trading on Tuesday, hitting $32.56. The company’s stock had a trading volume of 1,776 shares, compared to its average volume of 114,009. The firm’s 50 day moving average price is $28.71. LeMaitre Vascular Inc has a twelve month low of $21.79 and a twelve month high of $38.99. The stock has a market capitalization of $641.28 million, a price-to-earnings ratio of 38.92, a price-to-earnings-growth ratio of 3.16 and a beta of 1.15.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Wednesday, July 24th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.02. LeMaitre Vascular had a net margin of 16.72% and a return on equity of 13.15%. The business had revenue of $29.48 million during the quarter, compared to the consensus estimate of $28.90 million. During the same quarter last year, the firm posted $0.43 EPS. LeMaitre Vascular’s revenue was up 9.1% compared to the same quarter last year. Equities research analysts predict that LeMaitre Vascular Inc will post 0.86 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 5th. Investors of record on Wednesday, August 21st will be given a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 1.04%. The ex-dividend date of this dividend is Tuesday, August 20th. LeMaitre Vascular’s payout ratio is currently 40.48%.

Several brokerages have recently commented on LMAT. Zacks Investment Research downgraded shares of ZEALAND PHARMA/S from a “buy” rating to a “hold” rating in a research report on Saturday. Lake Street Capital raised their price objective on shares of LeMaitre Vascular from $27.00 to $34.00 and gave the stock a “hold” rating in a research report on Thursday, July 25th. Barrington Research reaffirmed a “market perform” rating on shares of HealthStream in a research report on Thursday, July 25th. BidaskClub downgraded shares of Westport Fuel Systems from a “buy” rating to a “hold” rating in a research report on Friday, July 19th. Finally, First Analysis raised shares of LeMaitre Vascular from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $29.00 to $37.00 in a research report on Thursday, July 25th. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. LeMaitre Vascular currently has an average rating of “Buy” and an average price target of $35.33.

In related news, Chairman George W. Lemaitre sold 66,037 shares of LeMaitre Vascular stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $34.45, for a total value of $2,274,974.65. Following the completion of the sale, the chairman now owns 3,171,124 shares of the company’s stock, valued at approximately $109,245,221.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 19.60% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Read More: Marijuana Stocks

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.